S94
Brachytherapy - Head & neck, skin, eye
ESTRO 2026
invasion (12%). Multiple risk factors were present in 24% of patients. Nearly half of the patients (52%) had positive p16 status. Interstitial HDR-IRT catheters were implanted intraoperatively, and radiation was delivered twice daily to a target volume encompassing the tumor with a 10–15 mm safety margin. Results:
outcomes. There was no significant change of the annual relative survival over the study period Conclusion: The current BT and PT protocols are effective in managing localized UM with similar survival outcomes. The choice of treatment modality should be based on individual tumor characteristics, reinforcing the need for a personalized treatment approach. Further studies are required to refine these treatment strategies to enhance patient outcomes. Keywords: Uveal Neoplasms; Brachytherapy; Proton Therapy OSIRIS-BOT: Organ Sparing using Interventional Radiotherapy (Brachytherapy) for early Invasive Squamous cell cancer of the Base of Tongue Tamer Soror 1 , Pierre-Alexander Justenhoven 1 , Warren Bacorro 2 , György Kovács 3 , Dirk Rades 1 , Karl-Ludwig Bruchhage 4 , Anke Leichtle 4 1 Radiation Oncology Department,, University of Lübeck/UKSH-CL, Lübeck, Germany. 2 Department of Radiation Oncology,, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines. 3 Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, Rome, Italy. 4 Department of Oto- Rhino-Laryngology and Head and Neck Surgery, University of Lübeck, Lübeck, Germany Purpose/Objective: Post-operative radiation is generally indicated for node negative T1-T2 base of tongue (BOT) cancers with risk factors as well as for node negative T3 cancers. This study evaluates the safety and efficacy of exclusive high-dose-rate interventional radiotherapy (HDR-IRT, brachytherapy) as a post-operative Poster Discussion 320
A total of 25 patients were included, with a median age of 61 years. The median total radiation dose was 30Gy, and median follow-up was 83 months. Three local failures were observed, all occurring within three years at 5, 27, and 27 months. No isolated nodal or distant failures were recorded. The 5-year organ/function preservation rate was 100%, with local failure-free survival at 70%, regional failure-free survival at 100%, and overall survival at 83%. Late toxicities occurred in 16 patients, comprising 22 grade 1–2 events. No major functional complications affecting swallowing, aspiration, or articulation were reported.Univariable analysis did not identify significant predictors of local failure. Factors analyzed included T-stage (p=0.36), grade (p=0.93), resection status (p=0.61), lymphatic invasion (p=0.088), vascular invasion (p=0.056), perineural invasion (p=0.69), p16 status (p=0.865), and brachytherapy dose ( ≤ 36 Gy vs. >36 Gy, p=0.21). Conclusion: The OSIRIS approach, integrating HDR-IRT with organ- preserving surgery, is an effective treatment for high- risk early-stage base of tongue squamous cell carcinoma offering excellent organ and function preservation alongside favorable long-term disease control and manageable toxicity. Keywords: Base of tongue, organ/ function preservation,
treatment modality. Material/Methods:
Digital Poster Highlight 544
We conducted a retrospective analysis of BOT cancer patients treated with HDR-IRT between 2008 and 2022, excluding recurrences and cases receiving combined external beam radiation therapy (EBRT) and brachytherapy. Risk factors for T1–T2 cancers included close margins (60%), positive margins (24%), vascular invasion (8%), lymphatic invasion (12%), and perineural
Ruthenium-106 Brachytherapy in Early Uveal Melanoma: Oncological Outcomes and Eye Preservation Stephanie Göller 1 , Justus Kaufmann 1 , Sophia Drabke 1 , Nina Gercek 1 , Liv-Annebritt Weimer 1 , Laura Oebel 1 ,
Made with FlippingBook - Share PDF online